◀ Back to SMAD1

AMH — SMAD1

Pathways - manually collected, often from reviews:

• NCI Pathway Database ALK2 signaling events: MIS/MISR2/ALK2 (dimer) complex (AMH-ACVR1-AMHR2) → SMAD1-5-8 (SMAD1/SMAD9/SMAD5) (modification, activates)
  Visser et al., Mol Endocrinol 2001, Clarke et al., Mol Endocrinol 2001
  Evidence: mutant phenotype, assay

Text-mined interactions from Literome

Clarke et al., Mol Endocrinol 2001 : MIS induced activation of a Gal4DBD-Smad1 but not a Gal4DBD-Smad2 fusion protein ... The BMP induced inhibitory Smad , Smad6, was up-regulated by MIS endogenously in Leydig cell derived lines and is expressed in male but not female Müllerian duct mesenchyme
Fynn-Thompson et al., Mol Cell Endocrinol 2003 : We continue to investigate the molecular mechanisms of MISRII expression and possible interactions between MIS regulated SMAD activation and cAMP signaling
Zhan et al., Development 2006 : MIS induces expression of Alk2, Alk3 and Smad8 , but downregulates Smad5 in the urogenital ridge
Gupta et al., Cancer Res 2007 (Breast Neoplasms) : Expression of dominant negative Smad1, in which serines at the COOH-terminal SSVS motif are converted to alanines, suppressed MIS induced Smad1 phosphorylation and impaired MIS stimulated Gro-beta promoter-driven reporter expression and Gro-beta mRNA ... These results show a novel interaction between MIS stimulated Smad1 and NF-kappaB signaling in which enhancement of NF-kappaB DNA binding and gene expression by phospho-Smad1 is dependent on the sequence of the kappaB consensus site within the promoter